Liquid Dosage Forms to Treat Cancer
AssigneeExelixis, Inc.
InventorsKhalid Shah, Gisela Schwab, Steven Lacy
Life of this patent
Estimating the term…
Abstract
This invention relates to a liquid pharmaceutical composition comprising cabozantinib to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma in patients in need thereof.
Claims19
A liquid pharmaceutical composition comprising a compound of formula I:
- or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein:
- R1 is halo;
- R2 is halo;
- and
- Q is CH or N.
A method of treating locally advanced or metastatic solid tumors, comprising administering a patient in need of such treatment, a liquid pharmaceutical composition comprising a compound of formula I:
- or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein:
- R1 is halo;
- R2 is halo;
- and
- Q is CH or N,
- and wherein administration of a single dose of the liquid pharmaceutical composition to a plurality of patients, provides an interpatient or intrapatient exposure variability (% CV for AUC0-t, AUC0-24, AUC0-72, AUC0-inf, or Cmax,) relative to a tablet formulation of less than 30%, or less than 25%, or less than 20%, or less than 19%, or less than 18%, or less than 17%, or less than 16%, or less than 15%, or less than 14%, or less than 13%, or less than 12%, or less than 11%, or less than 10%.
The liquid pharmaceutical composition according to claim 19, wherein the amount of compound 1, or a pharmaceutically acceptable salt thereof present in the liquid formulation is about 140 mg, or about 120 mg, or about 80 mg, or about 60 mg, or about 40 mg, or about 20 mg.
Dependencies are inferred from the claim text.